United Therapeutics CEO Martine A. Rothblatt reports disposal of $5.26 million in common shares

UTHR•2026-10-21

United Therapeutics CEO Martine A. Rothblatt sold 9,500 common shares on October 20, 2026, at weighted-average prices ranging from $546.8428 to $563.5646 per share.

1. Share transactions

Rothblatt also exercised 9,500 stock options at $117.76 per share. After the transactions, a trust held 324,443 common shares and 195,410 options, while Rothblatt directly owned 40,513 shares.

Sources

United Therapeutics CEO Martine A. Rothblatt reports disposal of $5.26 million in common shares

Sec

United Therapeutics CEO Martine A. Rothblatt reports disposal of $5.26 million in common shares

1. Share transactions

Related News

J.Jill EVP, CFO and COO Mark W. Webb reports sale of common shares worth $122,600

As AI accelerates cyberattacks, N-able and SentinelOne expand strategic partnership

Brandywine Realty Trust Q3 net loss narrows on higher property sales

Sources

United Therapeutics CEO Martine A. Rothblatt reports disposal of $5.26 million in common shares

VS Media changes name to Forcendra Holding

Qualys Chief Legal Officer Bruce K. Posey reports sale of 881 shares worth $166,962.9729